Time is always of the essence in clinical trials. But when competitors have the lead in bringing an alternative therapy to market, “the need for speed” takes on a whole new focus. This was the case with one top tier global pharmaceutical company that was just beginning its development programme for several infectious disease indications. Meanwhile, competitors for one of the compound’s primary indications were further along the regulatory pathway. Could Almac help the trial sponsor close the gap through technology to better manage patients, clinical supplies, and trial data?